Media centre
What can you do to help us close the gap in bowel cancer care?
Sunday, February 4, is World Cancer Day, and we’re calling on you to play your part in creating a bowel cancer-free world.
While we live in a time of awe-inspiring advancements in (bowel) cancer prevention, diagnosis and treatment, many who seek cancer care hit barriers at every turn.
This year’s World Cancer Day campaign is all about working together to reimagine a world where millions of preventable cancer deaths are saved and access to life-saving cancer treatment and care is equitable for all.
This year’s World Cancer Day campaign is all about working together to reimagine a world where millions of preventable cancer deaths are saved and access to life-saving cancer treatment and care is equitable for all.
- Details
Play For Purpose is the ultimate not-for-profit raffle!
Every ticket gives you the chance to win awesome prizes, all while supporting Bowel Cancer Australia.
Raffle tickets are just $10, with a guaranteed minimum of $5 directly supporting the charity.
- Details
A new oral treatment (tablet) called divarasib (GDC-6036) has proven effective in treating metastatic bowel cancer with a KRAS G12C mutation.
In a phase 1 trial published in Nature Medicine on 5 December, 62% of people with KRAS G12C mutated bowel cancer achieved a positive response to a combined treatment of divarasib and Erbitux (cetuximab).
- Details
A persistent change in bowel habit, especially more frequent and/or loose, diarrhoea-like motions for several weeks is a potential sign of bowel cancer.
Knowing what’s normal (for you), makes it easier to spot any changes in your bowel habit.
However, if a change lasts for more than two weeks, it could be a sign that something isn’t right, and you should discuss it straight away with your GP.
Today, for World Toilet Day, we are bringing your attention to the Bristol Stool Chart.
- Details
A new Australian study published in The Lancet suggests population-wide genetic screening for hereditary breast and ovarian cancer, familial hypercholesterolemia and Lynch syndrome, in people aged 18 to 40, would be cost effective and save lives.
Currently, around one in 75 people are at high genetic risk of one of these conditions, yet most are unaware of the risk or implications.
Experts at Monash University simulated a model of 8.3 million adults (Australia’s population aged 18 to 40) and their lifetime to age 80, assuming 50% would take part in the genetic screening.
- Details
Yesterday, the FDA has approved a new oral medicine called Fruzaqla (fruquintinib) for the treatment of patients with previously treated metastatic bowel cancer.
Fruquintinib is a type of targeted therapy that blocks a protein called 'vascular endothelial growth factor receptor' (VEGFR).
It is the first chemotherapy-free treatment option to be approved for metastatic bowel cancer in more than a decade, according to Takeda, the drug’s manufacturer.
- Details
In Australia, 1-in-9 new bowel cancer cases (1,716) occur in people under the age of 50 each year. Bowel cancer is the second most common cancer in women after breast cancer.
Bowel cancer treatment can come with fertility risks and understanding the options for preservation of fertility is an important consideration for many patients.
Just as all other side effects are discussed, possible impacts on reproductive function and fertility should be part of any discussion with your treating specialist before starting treatment for bowel cancer.
- Details
A key five-year Bowel Cancer Australia campaign has reached a milestone with updated clinical practice guidelines lowering the bowel cancer screening start age recently endorsed by the National Health and Medical Research Council (NHMRC).
For the first time, population screening (for people at average risk of developing bowel cancer, i.e., without any symptoms) is recommended every two years for people aged 45-74 (previously 50-74), along with a lowering of the National Bowel Cancer Screening Program (NBCSP) start age from 50 to 45.
People aged 40-44 (previously 45-49) are also able to request screening via their healthcare professional prior to receiving their first NBCSP invitation.
- Details
HER2 (also known as ERBB2), human epidermal growth factor receptor-2, is a gene that plays a role in the control of cell growth and cell survival.
Some cells may have an increased number of copies of the HER2 gene (overamplification) which can cause the cells to make too many HER2 receptors (overexpression). When these changes occur, they allow abnormal cell growth and survival.
- Details
